SEC Tracker
Get the app

Unite Acquisition 1 APTN

Unite Acquisition 1 Q3 FY24: net loss $30K; diluted EPS −$0.01

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Unite Acquisition 1 reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$30KAgainst −$43K in Q3 FY2310-Q income statement, on EDGAR
  2. Diluted EPS−$0.01Against −$0.01 in Q3 FY2310-Q income statement, on EDGAR
  3. Cash and cash equivalents$322−15% from $380 in Q3 FY2310-Q balance sheet, on EDGAR
  4. Cash from operations−$25KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Unite Acquisition 1 files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Artelo Biosciences ARTL public float $9M, Jun 30, 2025
  2. Bioxytran BIXT public float $9M, Jun 30, 2025
  3. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  4. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  5. TherapeuticsMD TXMD public float $9M, Jun 30, 2025